Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 23, 2021, Eli Lilly and Company (the "Company") entered into a multi-year research collaboration and licensing agreement with Lycia Therapeutics, Inc. ("Lycia"). In connection with the Company's entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company's Board of Directors, effective August 23, 2021. Dr. Bertozzi's decision to resign as a director did not arise from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On August 25, 2021, the Company issued a press release announcing Dr. Bertozzi's resignation from the Company's Board of Directors. A copy of the release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


Exhibit No.            Description
  99.1                   Press Release of Eli Lilly and Company, dated August 25, 2021.
                       Cover Page Interactive Data File (embedded within the Inline XBRL
104                    document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses